AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2015-06-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 467
- Registration Number
- NCT00641056
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2008-03-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1600
- Registration Number
- NCT00638391
Casodex - Nolvadex Combination
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00637871
Barrett's Esophagus - 315 - 3 Way Cross-Over
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT00637559
Barrett's Esophagus - 315 - 3 Way Cross Over
Phase 4
Completed
- Conditions
- Barrett's Esophagus
- Interventions
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT00637988
Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)
Phase 4
Completed
- Conditions
- HeartburnGastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 248
- Registration Number
- NCT00637845
A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: placebo tabletDrug: placebo once weekly
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 514
- Registration Number
- NCT00637273
- Locations
- 🇲🇽
Research Site, Toluca, Mexico
Gynecomastia Extension Study
Phase 3
Completed
- Conditions
- Gynecomastia
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00637182
Ph II Early BC Pre-Surgical Biologic Study
Phase 2
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT00637026
ZAP, US. Zomig for Appropriate for Primary Care
Phase 4
Completed
- Conditions
- Migraine
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2009-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00637286
© Copyright 2025. All Rights Reserved by MedPath